🇺🇸 FDA
Patent

US 10738046

Substituted pyrido[3,4-b]pyrazines as GPR6 modulators

granted A61PA61P1/14A61P25/00

Quick answer

US patent 10738046 (Substituted pyrido[3,4-b]pyrazines as GPR6 modulators) held by Takeda Pharmaceutical Company Limited expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P1/14, A61P25/00, A61P25/14, A61P25/16